X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
adolescent (1) 1
adult (1) 1
aged (1) 1
antiviral agents - administration & dosage (1) 1
antiviral agents - adverse effects (1) 1
antiviral agents - therapeutic use (1) 1
boceprevir (1) 1
care and treatment (1) 1
clinical trials (1) 1
double-blind method (1) 1
drug therapy, combination - methods (1) 1
female (1) 1
gastrointestinal diseases (1) 1
genetic aspects (1) 1
genotype (1) 1
headache - chemically induced (1) 1
health aspects (1) 1
hepacivirus - classification (1) 1
hepacivirus - pathogenicity (1) 1
hepatitis c (1) 1
hepatitis c, chronic - drug therapy (1) 1
hepatitis c, chronic - virology (1) 1
humans (1) 1
index medicus (1) 1
infectious disease (1) 1
infectious diseases (1) 1
inhibitors (1) 1
interferon (1) 1
interferon-alpha - administration & dosage (1) 1
interferon-alpha - therapeutic use (1) 1
liver cirrhosis (1) 1
liver cirrhosis - pathology (1) 1
male (1) 1
middle aged (1) 1
nausea - chemically induced (1) 1
plus ribavirin (1) 1
polyethylene glycols - administration & dosage (1) 1
polyethylene glycols - therapeutic use (1) 1
product development (1) 1
protease inhibitors (1) 1
proteases (1) 1
psi-7977 (1) 1
recombinant proteins - administration & dosage (1) 1
recombinant proteins - therapeutic use (1) 1
ribavirin - administration & dosage (1) 1
ribavirin - therapeutic use (1) 1
rna, viral - analysis (1) 1
secondary prevention (1) 1
sofosbuvir (1) 1
telaprevir (1) 1
time factors (1) 1
treatment outcome (1) 1
uridine monophosphate - administration & dosage (1) 1
uridine monophosphate - analogs & derivatives (1) 1
uridine monophosphate - therapeutic use (1) 1
viral antigens (1) 1
virus-infection (1) 1
young adult (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Infectious Diseases, The, ISSN 1473-3099, 2013, Volume 13, Issue 5, pp. 401 - 408
Summary Background Protease inhibitors have improved treatment of infection with hepatitis C virus (HCV), but dosing, a low barrier to resistance, drug... 
Infectious Disease | PSI-7977 | INFECTIOUS DISEASES | PLUS RIBAVIRIN | VIRUS-INFECTION | TELAPREVIR | BOCEPREVIR | INHIBITORS | Recombinant Proteins - therapeutic use | Uridine Monophosphate - administration & dosage | Nausea - chemically induced | Humans | Middle Aged | Hepatitis C, Chronic - virology | Hepacivirus - pathogenicity | Male | Secondary Prevention | Polyethylene Glycols - therapeutic use | Young Adult | Time Factors | Ribavirin - administration & dosage | Adult | Female | Headache - chemically induced | Uridine Monophosphate - therapeutic use | Double-Blind Method | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | RNA, Viral - analysis | Genotype | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Polyethylene Glycols - administration & dosage | Recombinant Proteins - administration & dosage | Interferon-alpha - administration & dosage | Drug Therapy, Combination - methods | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | Adolescent | Liver Cirrhosis - pathology | Aged | Hepacivirus - classification | Sofosbuvir | Care and treatment | Protease inhibitors | Proteases | Gastrointestinal diseases | Clinical trials | Product development | Genetic aspects | Interferon | Hepatitis C | Health aspects | Liver cirrhosis | Viral antigens
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.